Top ▲

Alopecia areata

Disease ID:1200
Name:Alopecia areata
Associated with:0 target
2 immuno-relevant ligands
circumscribed alopecia
A hypersensitivity reaction type II disease causing loss of head and body hair, initially causing bald spots.
Database Links
Disease Ontology: DOID:986


No target related data available for Alopecia areata


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Phase 2 clinical candidate for alopecia areata (see NCT02684097).
Clinical Use: Tralokinumab reached Phase 3 clinical trials for uncontrolled asthma, and atopic dermatitis, and Phase 2 for alopecia areata. Click here to link to's listing of Phase 3 tralokinumab trials. In addition, Phase 2 trials are investigating tralokinumab as a treatment for idiopathic pulmonary fibrosis (IPF, NCT01629667 and NCT02036580). Business reports online indicate that AstraZeneca have discontinued tralokinumab development foa asthma as it showed no benefit over placebo in their STRATOS 2 and TROPOS late-stage asthma trials [1].
The EMA approved LEO Pharma's tralokinumab product Adtralza® in July 2021, as a treatment for severe atopic dermatitis that cannot be controlled by topical drugs. FDA approval for this indication followed at the end of 2021. | View clinical data
ritlecitinib 2
Immuno Disease Comments: Phase 2b/3 clinical candidate for AA (NCT03732807). In August 2021, Pfizer announced that ritlecitinib had met its primary endpoint (reduction in hair loss) in this study. Results from phase 2a NCT02974868 comparing ritlecitinib and brepocitinib with placebo at 24 weeks were published by King et al. (2021).
Clinical Use: PF-06651600 has completed Phase 2 clinical trials for rheumatoid arthritis and ulcerative colitis and it has advanced to Phase 2b/3 in alopecia areata patients. Click here to link to's full list of PF-06651600 trials. | View clinical data
Bioactivity Comments: PF-06651600 exhibits favourable selectivity against a screening panel of 305 kinases in vitro, and shows measurable inhibition of 7 of the 10 other kinases which share a cysteine residue analogous to Cys-909 in the JAK3 ATP binding site (these were BMX, ITK, TXK, TEC, BTK, BLK and HER4) [3].
ATP concentration for JAK3 is 4 μM at Km and for JAK1 is 40 μM at Km, but some assays reported in [3] were carried out at 1 mM ATP . | View biological activity


Show »

1. Adams B. Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease. Accessed on 09/02/2018. Modified on 09/02/2018.,

2. King B, Guttman-Yassky E, Peeva E, Banerjee A, Sinclair R, Pavel AB, Zhu L, Cox LA, Craiglow B, Chen L et al.. (2021) A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. J Am Acad Dermatol, 85 (2): 379-387. [PMID:33757798]

3. Thorarensen A, Dowty ME, Banker ME, Juba B, Jussif J, Lin T, Vincent F, Czerwinski RM, Casimiro-Garcia A, Unwalla R et al.. (2017) Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. J Med Chem, 60 (5): 1971-1993. [PMID:28139931]